Balversa,
erdafitinib,
JNJ-42756493,
Erdafitinib,
1346242-81-6,
JNJ-42756493,
UNII-890E37NHMV,
890E37NHMV,
N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine,
Erdafitinib [USAN:INN],
Erdafitinib (USAN/INN),
jnj-42756493-erdafitinib,
GTPL9039,
SCHEMBL2583760,
CHEMBL3545376,
Erdafitinib; JNJ-42756493,
Erdafitinib (JNJ-42756493),
JNJ-42756493 (Erdafitinib),
BCP20346,
EX-A2564,
MFCD28502040,
s8401,
AKOS030526429,
compound 4 [WO2011135376],
ZINC168520308,
CS-4988,
DB12147,
SB16854,
JNJ42756493,
1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-,
AC-30222,
AK547250,
AS-35040,
HY-18708,
JNJ 42756493,
N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine,
D10927,
Erdafitinib,JNJ-42756493 ,JNJ 42756493 ,JNJ42756493,
5SF,
Erdafitinib [INN],
A15957,
~{n}'-(3,5-Dimethoxyphenyl)-~{n}'-[3-(1-Methylpyrazol-4-Yl)quinoxalin-6-Yl]-~{n}-Propan-2-Yl-Ethane-1,2-Diamine,